Published in final edited form as:

J Am Acad Dermatol. 2014 October ; 71(4): 633–641. doi:10.1016/j.jaad.2014.05.001.

Patient-Reported Outcomes in Psoriasis Patients with Clear Versus Almost Clear Skin in the Clinical Setting

Junko Takeshita, MD, PhD^{1,2}, Kristina Callis Duffin, MD, MS³, Daniel B. Shin, MS^{1,2}, Gerald G. Krueger, MD³, Andrew D. Robertson, PhD⁴, Andrea B. Troxel, ScD², Abby S. Van Voorhees, MD¹, and Joel M. Gelfand, MD, MSCE.^{1,2}

¹Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia

²Department of Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia

³Department of Dermatology, University of Utah School of Medicine, Salt Lake City

⁴The National Psoriasis Foundation, Portland, Oregon

Abstract

Background—There is little evidence to guide the establishment of treatment goals for moderate-to-severe psoriasis in the clinical setting.

© 2014 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Correspondence: Junko Takeshita, MD, PhD, Department of Dermatology, University of Pennsylvania, 1463 Penn Tower, One Convention Ave, Philadelphia, PA 19104, Junko.Takeshita@uphs.upenn.edu.

Author Contributions: Dr. Takeshita had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Takeshita, Gelfand, Callis Duffin, and Krueger. *Acquisition of data:* Gelfand, Callis Duffin, Krueger, Shin, and Van Voorhees. *Analysis and interpretation of data:* Takeshita, Gelfand, Shin, and Troxel. *Drafting of the manuscript:* Takeshita and Gelfand. *Critical revision of the manuscript for important intellectual content:* Takeshita, Shin, Callis Duffin, Krueger, Robertson, Shin, Troxel, Van Voorhees, and Gelfand. *Statistical analysis:* Takeshita, Shin, and Troxel. *Obtained funding:* Gelfand and Callis Duffin. *Administrative, technical, or material support:* Robertson and Shin. *Study supervision:* Gelfand, Krueger.

Financial Disclosure: Dr. Callis Duffin was an investigator, consultant, and/or speaker for Abbvie, Amgen, ApoPharma, Bristol-Myers Squibb, Celgene, Eli Lilly, Genzyme, Incyte, Janssen Biologics/Centocor, NovoNordisk, Pfizer, and Wyeth, receiving honoraria and/or salary; served on the advisory board of Amgen; and received residency/fellowship program funding from Abbvie Laboratories and Amgen. Dr. Gelfand served as a consultant for Abbvie, Amgen Inc., Celgene Corp, Eli Lilly, Merck, Janssen Biologics (formerly Centocor), Novartis Corp, and Pfizer Inc., receiving honoraria; had grants or has pending grants from Abbvie, Amgen Inc., Eli Lilly, Genentech Inc., Novartis Corp, and Pfizer Inc.; and received payment for continuing medical education work related to psoriasis. Dr. Krueger served as a consultant for Abbvie, Amgen Inc., and Janssen Biologics; had grants or has pending grants from Abbvie and Amgen Inc.; and received payment for lectures and travel-related expenses from Abbvie, Amgen Inc., and Janssen Biologics. Dr. Robertson is employed by the National Psoriasis Foundation, which receives unrestricted financial support from companies that make products used to treat psoriasis and psoriatic arthritis, including Abbvie, Amgen, Inc., Celgene, Eli Lilly and Co., Galderma Laboratories, L.P., Janssen Biotech Inc., Leo Pharma Inc., Novartis, Pfizer, Inc., and Stiefel, a GSK Company. Dr. Robertson has also served as an uncompensated member of advisory boards at Abbvie and Merck. Dr. Takeshita has received payment for continuing medical education work related to psoriasis. Dr. Van Voorhees served on advisory boards for Amgen Inc., Abbvie, Genentech Inc., Warner Chilcott, Leo, and Janssen Biologics; served as an investigator for Amgen Inc., Abbvie, receiving grants; served as a consultant for Amgen Inc.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Objective—To compare Dermatology Life Quality Index scores and prescription topical medication use between patients with clear versus almost clear skin.

Methods—Multicenter cross-sectional study of 97 patients with clear skin and 441 patients with almost clear skin receiving current systemic therapy or phototherapy for a primary indication of plaque psoriasis evaluated at one of ten US outpatient dermatology sites participating in the Dermatology Clinical Effectiveness Research Network.

Results—In adjusted analyses, patients with clear versus almost clear skin were more likely to report no impact of psoriasis on quality of life (relative risk 1.60; 95% confidence interval, 1.37–1.86). Patients with clear versus almost clear skin were also more likely to report no prescription topical medication use in the preceding week (relative risk 2.08; 95% confidence interval, 1.73–2.49).

Limitations—Cross-sectional design prohibits longitudinal assessment of outcomes.

Conclusions and Relevance—Clinically important differences in quality of life and prescription topical medication use exist between patients with clear versus almost clear skin. Collectively, our results indicate that achievement of clear skin may be an important clinical distinction among patients with moderate-to-severe psoriasis.

Keywords

Psoriasis; Quality of life; Dermatology Life Quality Index; Patient-reported outcome; Physician Global Assessment; Psoriasis Area and Severity Index

INTRODUCTION

Psoriasis is a common chronic inflammatory disease of the skin that affects 2–3% of the population.¹ Particularly when more severe, psoriasis is increasingly recognized as having important physical and psychosocial effects that extend beyond the skin.^{2,3} Despite the rapid expansion of treatment options for moderate-to-severe psoriasis over the last decade, therapies often fail to achieve or maintain skin clearance in patients, and patients are frequently dissatisfied with their treatments.⁴ In an effort to improve treatment outcomes and satisfaction, guidelines for appropriate psoriasis treatment largely based on expert consensus have been created in Canada, Europe, the United Kingdom, and Australia.^{5–9} Recognizing the evidence that suggests that typical physician-reported measures of psoriasis severity (e.g., body surface area [BSA] affected, Psoriasis Area and Severity Index [PASI], and Physician Global Assessment [PGA]) may not adequately capture psoriasis severity from the patient's perspective,^{10,11} patient-reported outcomes which are metrics that assess a patient's health status or quality of life [QoL] from the patient perspective are increasingly being used to guide clinical care. In fact, recommendations for treatment goals in many of the aforementioned psoriasis treatment guidelines incorporate both physician- and patient-reported outcomes (e.g., the Dermatology Quality Life Index (DLQI), a validated and widely used dermatology-specific health-related quality of life [HRQoL] measure)^{12,13} as measures of treatment response. Yet, a gold standard definition for adequate treatment response and universally accepted treatment target remain to be established.

Psoriasis Area and Severity Index (PASI)-75, defined by at least 75% improvement in PASI score, is the mostly widely used measure of clinical efficacy and is a suggested treatment goal in most guidelines.^{6–9} Both PASI-50¹⁴ and PASI-90^{15,16} have also been suggested to represent important clinical endpoints by some. The utility of PASI-based outcome measures in the real-world clinical setting remains unclear, however, as the PASI score is not commonly used outside the clinical trial setting, and it has little utility as a single score.

PGA is increasingly being used to define treatment efficacy in clinical trials and has been suggested to be a reasonable and more feasible alternative to the PASI score as a measure of psoriasis severity in the clinical setting.¹⁷ Several versions of the PGA exist, and, in clinical trials, treatment efficacy is often defined by the proportion of patients having clear or almost clear skin corresponding to a PGA score 1.¹⁷ PGA-defined clear or almost clear skin is an alternative treatment goal to PASI-75 and the patient-reported outcome measure, Dermatology Life Quality Index (DLQI) score 1, according to the European S3 Guidelines.⁶ It remains unknown, however, if complete skin clearance itself should be a treatment goal, particularly from the patient perspective. Thus, the primary aim of this study was to determine if physician-reported differences in patients with clear versus almost clear skin as defined by PGA are associated with significant differences in patient-reported HRQoL as measured by the DLQI in the routine clinical practice setting. We hypothesized that patients with clear skin would be more likely to report lower DLQI scores corresponding to lesser impact of their skin disease on QoL compared to patients with almost clear skin. Secondly, especially since topical medication use has been associated with poor treatment satisfaction,^{18–20} we also aimed to assess the differences in prescription topical medication use in patients with clear versus almost clear skin.

METHODS

Study Design and Participant Protection

We conducted a cross-sectional study to compare patient-reported outcomes among patients with minimal psoriasis activity (i.e., clear or almost clear skin). The study was approved by the University of Pennsylvania and University of Utah institutional review boards, and verbal informed consent was obtained from all patients. The study was conducted in accordance with the Declaration of Helsinki and reported in accordance with the STROBE guidelines.²¹

Setting

Data were collected by 12 clinicians (10 dermatologists and 2 physician assistants) who are members of the Dermatology Clinical Effectiveness Research Network (DCERN). DCERN includes 2 academic medical centers (University of Pennsylvania and University of Utah, each with a hospital-based site and a separate community-based site) and 6 private practices in Georgia, Pennsylvania, New York, and Colorado (see www.dermcern.org for details). Patient data were collected prospectively at a single, regularly scheduled clinic appointment from February 2010 through June 2011.

Participants

As previously described in detail,²² broad inclusion criteria were used to enroll consecutive patients seen by their dermatology provider in DCERN practices for a routine follow-up appointment in order to minimize selection bias. Eligible participants included patients who met at least one of the following criteria to define moderate-to-severe psoriasis: were currently receiving or had previously received systemic therapy or phototherapy prescribed by a dermatology provider for treatment of psoriasis, or were candidates for systemic therapy with a documented history of at least 5% body surface area (BSA) involvement. In the analyses presented, patients were included if they were currently receiving any systemic therapy or phototherapy for a primary indication of plaque psoriasis and if they had clear or almost clear skin (PGA < 1.5) as defined by a 6-point PGA scale of psoriasis lesions (scored separately for erythema [0, no evidence of erythema, hyperpigmentation may be present; 1, faint erythema; 2, light red coloration; 3, moderate red coloration; 4, bright red coloration; 5, dusky to deep red coloration], induration [0, no evidence of plaque elevation; 1, minimal plaque elevation, 0.25mm; 2, mild plaque elevation, 0.5mm; 3, moderate plaque elevation, 0.75mm; 4, marked plaque elevation, 1mm; 5, severe plaque elevation, 1.25mm], and scaling [0, no evidence of scaling; 1, minimal, occasional fine scale over <5% of the lesion; 2, mild, fine scale dominates; 3, moderate, coarse scale predominates; 4, marked, thick, nontenacious scale predominates; 5, severe, very thick tenacious scale predominates] and then averaged to produce a single static score [0, clear; 1, minimal; 2, mild; 3, moderate; 4, marked; and 5, severe; note: averaged scores should be rounded to the nearest whole number]).^{23,24} This 6-point PGA scale was chosen based on its use in at least two large psoriasis clinical trials^{23,24} and national expert consensus including representation from the National Psoriasis Foundation.

Variables

Detailed patient and provider level data including medical history, current and past psoriasis treatments, sociodemographic factors, psoriasis characteristics, height, weight, and alcohol and tobacco use history were collected by trained study coordinators using standardized case report forms and via patient self-report with confirmation by the patient's dermatology clinic record and assessments by the clinician investigators.²² The main exposure was PGA score dichotomized as clear (PGA=0) or almost clear ($0 < \text{PGA} < 1.5$) skin. As a secondary exposure, PASI was used to define clear (PASI=0) and almost clear ($0 < \text{PASI} < 3$) skin (PASI score cutoff was based on a receiver operating characteristic analysis comparing PASI scores with PGA scores). The primary outcome measure was DLQI, a skin-specific HRQoL measure that is widely used in clinical trials and has been shown to be valid and reliable in the clinical setting.^{12,25,26} The DLQI outcome was dichotomized as no effect (0–1) or small to extremely large effect (2–30) on quality of life (QoL).²⁷ The secondary outcome was prescription topical medication use in the preceding week which was dichotomized as no versus any use. All other variables served as potential confounders. Current treatment and prescription topical medication use (in the primary analysis only) were considered potential effect modifiers.

Study Size

Target enrollment was established for the primary comparative effectiveness study,²² within which the current study was nested. This study was descriptive in nature, thus the sample size was not determined a priori. The maximum number of eligible subjects was included, and all effect measures are reported with 95% CIs.

Statistical Analysis

First, univariate analyses were conducted using unpaired, 2-tailed *t* tests and Wilcoxon rank-sum tests for comparisons of continuous data; and Fisher's exact test for categorical data. We performed modified Poisson regression with robust error variance²⁸ to determine which factors were independently associated with the primary and secondary outcomes. Being almost clear of psoriasis served as the reference for all analyses. To build our multivariable model, we used a purposeful selection approach in which age, sex, and any covariates (i.e., race, ethnicity, marital status, education, income, health insurance type, dermatologist's practice setting, smoking history, drinking history, body mass index, total number of comorbid diseases, age of psoriasis onset, psoriasis severity at its worst, family history of psoriasis, presence of psoriatic arthritis, and Fitzpatrick skin type) with significance at *P* 0.20 in univariate analyses were included in the multivariable model as potential confounding variables.^{29,30} No variables were found to be collinear. Current treatment and prescription topical medication use were considered part of the causal pathway between exposure and primary outcome and, thus, were not considered potential confounders. Nonsignificant covariates (*P* > 0.10) were eliminated from the multivariable model if their removal did not change the risk ratio estimates of the exposure variable by more than 10%. Effect modification by current treatment (both treatment type and number of treatments) and by prescription topical medication use were each assessed and included in the multivariable model if the interaction terms were significant (*P* < 0.10). Model fit was assessed using goodness-of-fit tests based on deviance and Pearson statistics. The modified Poisson modeling approach was used to yield the clinically relevant statistic of relative response rate (i.e., relative risk; RR) which was then used to calculate the relative response difference (RD) and the number needed to treat (NNT). We performed sensitivity analyses including using an alternative outcome definition of DLQI ≤ 5 (no to small effect on QoL), stricter definition of almost clear defined by 0 < PGA ≤ 1, limiting the study population to patients with current psoriasis extent of BSA < 3%, excluding patients who reported their psoriasis to be mild at its worst state, and excluding patients with psoriatic arthritis. Missing data did not exceed 1% for any of the variables analyzed, and patients with missing data were excluded from analyses.

RESULTS

The characteristics of 97 patients with clear and 441 patients with almost clear skin on current psoriasis therapy are summarized in Table 1. Patients with clear skin were older than patients with almost clear skin with mean (standard deviation; SD) ages of 52.6 (13.5) and 47.3 (15.5), respectively, (*p*=0.002). Men and women were nearly equally represented in both groups, and the majority of patients were Caucasian. There were no significant differences in median BMI or smoking status between groups. Drinking status was

significantly different with more patients with clear (45.4%) versus almost clear skin (27.4%) reporting no alcoholic drinks in the past year ($p=0.001$). Median number of comorbidities was greater among patients with clear (3; IQR, 1–5) versus almost clear skin (2; IQR, 1–4; $p=0.05$).

The psoriasis characteristics of patients with clear and almost clear skin are summarized in Table 2. Median age of psoriasis onset was higher among patients with clear (30 years; IQR, 18–41) versus almost clear skin (23 years; IQR, 15–38; $p=0.02$). Median psoriasis duration and proportions of patients with family history of psoriasis and with physician-diagnosed psoriatic arthritis were similar in the two groups. More patients with clear (71.1%) versus almost clear skin (55.3%) reported their psoriasis to be severe in its worst state ($p=0.01$). Total number of current therapies was similar between the two groups, and there were no significant differences in the proportions of patients on single or combination therapies. However, among patients on single therapy, patients with clear skin were more likely to be on biologic monotherapy (clear 72.7%; almost clear 54.2%; $p=0.006$) and less likely to be receiving phototherapy (clear 6.1%; almost clear 22.0%; $p=0.002$) than patients with almost clear skin. Treatment with single oral systemic therapy was similar in both groups. Among those on combination therapy, patients with clear skin were more likely to be on combined biologic and oral systemic therapy than those with almost clear skin (clear 77.4%; almost clear 46.0%; $p=0.003$). Fewer patients with clear (22.7%) versus almost clear skin (65.5%) reported any prescription topical medication use in the last week ($p<0.001$).

In univariate analyses, DLQI scores of patients with clear versus almost clear skin were significantly different (Table 3). Median DLQI score for patients with clear skin was 0 (IQR, 0–1), corresponding to having no effect on QoL while that for patients with almost clear skin was 2 (IQR, 0–5), corresponding to having small effect on QoL ($p<0.001$). Similarly, a higher proportion of patients with clear (76.3%) versus almost clear skin (44.2%) had DLQI score ≤ 1 which corresponds to having no effect on QoL ($p<0.001$).²⁷ Importantly, based on European guidelines that identify DLQI score >5 as an indication of treatment failure and thus a criterion for therapy change,⁷ only 2.1% of patients with clear skin versus 19.4% of patients with almost clear skin exhibited inadequate treatment response ($p<0.001$).

In multivariable analyses using DLQI ≤ 1 (no effect on QoL) as the outcome and PGA score to define clear and almost clear skin, patients with clear skin were more likely to report that psoriasis had no effect on their QoL than patients with almost clear skin (RR 1.60; 95% CI, 1.37–1.86) after adjusting for confounding factors (Table 4). No significant effect modification by current treatment (neither treatment type nor number of treatments) or by prescription topical medication use was identified. The risk difference between patients with clear and almost clear skin was significant at 0.25 (95% CI, 0.16–0.38; data not shown), corresponding to an NNT of 3.8 (95% CI, 2.8–6.4). The clinical significance of NNT in this scenario is that four patients (rounded up from 3.8 per convention) with almost clear skin would need to achieve skin clearance in order for one additional patient to reach the DLQI response of no effect on QoL over what would be expected if those same patients persisted with almost clear skin. In secondary multivariable analyses of prescription topical medication use, patients with clear skin were twice as likely to report no prescription topical

medication use in the preceding week compared to patients with almost clear skin (RR 2.08; 95% CI, 1.73–2.49), resulting in an NNT of 2.7 (95% CI, 2.2–3.8) (data not shown).

In sensitivity analyses, we redefined our primary outcome as DLQI ≤ 5 (no to small effect on QoL). We found an attenuated but still significantly increased response rate among patients with clear skin compared to patients with almost clear skin (RR 1.19; 95% CI, 1.12–1.27), resulting in a slight increase in NNT over our primary analysis to 6.4 (95% CI, 5.0–11.5). Our findings were also robust to the following: stricter definition of almost clear defined by 0 < PGA ≤ 1 , use of PASI score to define clear and almost clear skin, limiting our study population to patients with BSA < 3% to further ensure that included patients truly had limited disease activity, exclusion of patients who reported their psoriasis at its worst to be mild, and exclusion of patients with psoriatic arthritis (Table 4).

DISCUSSION

In this study we compared a validated and widely used patient-reported outcome measure, the DLQI, between patients with clear and almost clear skin as defined by PGA and PASI scores determined during routine dermatologic care in academic and private practices across the United States. In univariate analyses, we found DLQI scores to be lower among patients with clear compared to almost clear skin. Importantly, nearly 20% of patients with almost clear skin compared to only 2% of patients with clear skin reported DLQI scores indicative of treatment failure according to European guidelines.⁷ In fully adjusted analyses, patients with clear skin were 50–60% more likely to report no effect on QoL than patients with almost clear skin. Our results were independent of the measure used to define clear and almost clear skin and were robust to exclusion of patients with current BSA ≥ 3 , indicating that our findings were representative of patients with truly limited psoriasis. Additionally, using an alternative outcome of no to small effect on QoL resulted in an attenuated but still significantly increased response rate among psoriasis patients with clear skin compared to those with almost clear skin.

Our study is the first to specifically compare HRQoL between patients with clear and almost clear skin evaluated during routine clinical follow-up. Our findings are novel in suggesting that clearance of psoriasis abrogates the negative impact that active psoriasis has on a patient's QoL and that clinically important improvements in QoL accompany the transition from almost clear to clear skin. Furthermore, we demonstrate that inadequate treatment response is more prevalent among patients with almost clear versus clear skin. Thus, overall, our results suggest that achieving skin clearance may be an important independent treatment endpoint especially from the patient perspective.

We also found clear skin to be associated with less prescription topical medication use compared to almost clear skin. Topical therapies for psoriasis are generally associated with poor treatment satisfaction, poor adherence due to low efficacy, treatment inconvenience, unsatisfactory cosmetic appearance of the medications, and undesired side effects with long term use.^{18–20,31–33} Thus our data suggest that a decrease in prescription topical medication use may contribute to improvements in QoL associated with skin clearance.

Strengths of our study include its broad inclusion criteria, patient population drawn from multiple clinical practices across the United States, and use of multivariable statistical models to account for potential confounding factors. Limitations include the cross-sectional design which does not allow for longitudinal assessment of the outcomes of interest. Additionally, patients included in our study were those currently receiving phototherapy or systemic treatment, and thus our findings may not be generalizable to those on topical treatment only. Though our analyses did not reveal any differences among therapies, our study may not have been adequately powered to detect therapy effects. Finally, our study does not address specific issues related to health-related decision-making, thus any differences in DLQI scores related to clear versus almost clear skin must be interpreted carefully with respect to treatment and other costs and benefits associated with achieving skin clearance.

In summary, this multi-center study of patient-reported outcomes among moderate-to-severe psoriasis patients with clear versus almost clear skin provides new insight into the impact of achieving skin clearance on HRQoL as measured by DLQI in the real-world clinical setting. Our findings collectively suggest an endpoint of skin clearance to be an important treatment goal. Future longitudinal studies and cost-effectiveness analyses are needed to further our understanding of the clinical impact of HRQoL differences that accompany the transition from almost clear to clear skin.

Acknowledgments

Funding/Support: This study was supported by grant RC1-AR058204 and K24-AR064310 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Dr. Gelfand), Dermatology Foundation Career Development Award (Takeshita), National Psoriasis Foundation Fellowship Award (Takeshita), Training Grants T32 GM 075766-6 (Takeshita) and T32-AR07465 (Shin) from the National Institutes of Health, and an unrestricted grant from Eli Lilly.

Role of the Sponsors: The sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; in the preparation or approval of the manuscript; or in the decision to submit the manuscript for publication. Eli Lilly participated in reviewing the manuscript only. All other sponsors had no role in review of the manuscript.

We would like to acknowledge Dermatology Clinical Effectiveness Research Network (DCERN) investigators including Drs. Jamie Weisman, Stephen M. Schleicher, Robert E. Kalb, Brian R. Sperber, Michael B. Stierstorfer, and Bruce A. Brod for their contribution to data collection.

ABBREVIATIONS AND ACRONYMS

BMI	Body mass index
BSA	Body surface area
CI	Confidence interval
DCERN	Dermatology Clinical Effectiveness Research Network
DLQI	Dermatology Life Quality Index
HRQoL	Health-related quality of life
IQR	Interquartile range

NNT	Number needed to treat
PASI	Psoriasis Area and Severity Index
PGA	Physician Global Assessment
PsA	Psoriatic arthritis
QoL	Quality of life
RD	Risk difference
RR	Relative risk
SD	Standard deviation

References

1. National Psoriasis Foundation. [Accessed July 24, 2012] http://www.psoriasis.org/netcommunity/learn_statistics
2. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. *JAMA Dermatol.* 2013; 149:1173–1179. [PubMed: 23925466]
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. *J Am Acad Dermatol.* 1999; 41:401–407. [PubMed: 10459113]
4. Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the national psoriasis foundation surveys, 2003–2011. *JAMA Dermatol.* 2013; 149:1180–1185. [PubMed: 23945732]
5. Canadian Guidelines for the Management of Plaque Psoriasis. 2009. <http://www.dermatology.ca/wp-content/uploads/2012/01/cdnpsoriasisguidelines.pdf>
6. Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. *J Eur Acad Dermatol Venereol.* 2009; 23 (Suppl 2):1–70. [PubMed: 19712190]
7. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. *Arch Dermatol Res.* 2011; 303:1–10. [PubMed: 20857129]
8. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Finlay AY, et al. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. *Br J Dermatol.* 2009; 161:987–1019. [PubMed: 19857207]
9. Baker C, Mack A, Cooper A, Fischer G, Shumack S, Sidhu S, et al. Treatment goals for moderate to severe psoriasis: an Australian consensus. *Australas J Dermatol.* 2013; 54:148–154. [PubMed: 23330815]
10. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. *J Psychosom Res.* 2001; 50:11–15. [PubMed: 11259795]
11. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmatization. *Physiol Behav.* 2000; 70:567–571. [PubMed: 11111012]
12. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin Exp Dermatol.* 1994; 19:210–216. [PubMed: 8033378]
13. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. *J Clin Pharm Ther.* 1998; 23:391–398. [PubMed: 9875689]

14. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. *J Am Acad Dermatol.* 2004; 50:859–866. [PubMed: 15153885]
15. Torii H, Sato N, Yoshinari T, Nakagawa H. Japanese Infliximab Study I. Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: an analysis of Japanese clinical trials of infliximab. *J Dermatol.* 2012; 39:253–259. [PubMed: 22211581]
16. Revicki DA, Willian MK, Menter A, Saurat JH, Harnam N, Kaul M. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. *Dermatology.* 2008; 216:260–270. [PubMed: 18187944]
17. Robinson A, Kardos M, Kimball AB. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis. *J Am Acad Dermatol.* 2012; 66:369–375. [PubMed: 22041254]
18. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM. Satisfaction with treatment among patients with psoriasis: a web-based survey study. *Br J Dermatol.* 2013; 169:398–405. [PubMed: 23565643]
19. Schaarschmidt ML, Umar N, Schmieder A, Terris DD, Goebeler M, Goerdts S, et al. Patient preferences for psoriasis treatments: impact of treatment experience. *J Eur Acad Dermatol Venerol.* 2013; 27:187–198. [PubMed: 22225546]
20. Callis Duffin K, Yeung H, Takeshita J, Krueger GG, Robertson AD, Troxel AB, et al. Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. *Br J Dermatol.* 2014; 170:672–680. [PubMed: 24266717]
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet.* 2007; 370:1453–1457. [PubMed: 18064739]
22. Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, et al. Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting. *Arch Dermatol.* 2012; 148:487–494. [PubMed: 22508874]
23. Centocor: briefing document for ustekinumab (CNTO 1275). Food and Drug Administration; Jun 17. 2008 <http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b1-02-CENTOCOR.pdf> [Accessed January 16, 2014]
24. Enbrel (etanercept) for the treatment of pediatric plaque psoriasis. Food and Drug Administration; Jun 18. 2008 <http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b2-01-FDA.pdf> [Accessed January 16, 2014]
25. Shikier R, Bresnahan BW, Stone SP, Thompson C, Koo J, Revicki DA. Validity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trials. *Health Qual Life Outcomes.* 2003; 1:53. [PubMed: 14613569]
26. Shikier R, Willian MK, Okun MM, Thompson CS, Revicki DA. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study. *Health Qual Life Outcomes.* 2006; 4:71. [PubMed: 17005043]
27. Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? *J Invest Dermatol.* 2005; 125:659–664. [PubMed: 16185263]
28. Zou G. A modified poisson regression approach to prospective studies with binary data. *Am J Epidemiol.* 2004; 159:702–706. [PubMed: 15033648]
29. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. *Source Code Biol Med.* 2008; 3:17. [PubMed: 19087314]
30. Hosmer, DW.; Lemeshow, S. *Applied Logistic Regression.* 2. New York, NY: John Wiley and Sons; 2000.
31. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. *J Eur Acad Dermatol Venerol.* 2012; 26 (Suppl 3):61–67. [PubMed: 22512682]

32. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. *J Dermatolog Treat.* 2013; 24:64–69. [PubMed: 21797808]
33. Fouere S, Adjadj L, Pawin H. How patients experience psoriasis: results from a European survey. *J Eur Acad Dermatol Venereol.* 2005; 19 (Suppl 3):2–6. [PubMed: 16274404]

Table 1

Baseline Characteristics of Patients with Clear or Almost Clear Skin.

Characteristic	Clear (PGA = 0) N = 97	Almost Clear (0 < PGA < 1.5) N = 441	P value ^a
Age, year			
Mean (SD)	52.6 (13.5)	47.3 (15.5)	0.002 ^b
Median (IQR)	52 (43, 63)	47 (35, 59)	0.002 ^c
Female Sex, N (%)	52 (53.6)	224 (50.8)	0.65
White Race, N (%)	83 (85.6)	394 (89.3)	0.29
Practice setting of dermatologist, N (%)			0.26
Academic	54 (55.7)	216 (49.0)	
Private	43 (44.3)	225 (51.0)	
Smoking status, N (%)			0.80
Current	15 (15.5)	71 (16.1)	
Past	30 (30.9)	150 (34.0)	
Never	52 (53.6)	220 (49.9)	
Current drinking status, N (%)			0.001
Heavy ^d	6 (6.2)	21 (4.8)	
Moderate	47 (48.4)	299 (67.8)	
None in last year	44 (45.4)	121 (27.4)	
BMI, median (IQR)	28.8 (24.4, 32.2)	28.1 (24.7, 32.8)	0.97 ^c
Total number of comorbidities, median (IQR)	3 (1, 5)	2 (1, 4)	0.05 ^c

^a Fisher's exact test^b Student's t-test^c Wilcoxon rank-sum test^d More than 2 drinks per day for men and more than 1 drink per day for women

Table 2

Psoriasis Characteristics of Patients with Clear or Almost Clear Skin.

Characteristic	Clear (PGA = 0) N = 97	Almost Clear (0 < PGA < 1.5) N = 441	P value ^a
Age of psoriasis onset, median (IQR), year	30 (18, 41)	23 (15, 38)	0.02 ^b
Psoriasis duration, median (IQR), year	20 (9, 33)	19 (8, 29)	0.33 ^b
Family history of psoriasis ^c , N (%)	33 (34.0)	182 (41.4)	0.71
Psoriasis extent at its worst, N (%)			0.01
Mild	5 (5.2)	53 (12.0)	
Moderate	23 (23.7)	144 (32.7)	
Severe	69 (71.1)	244 (55.3)	
Psoriatic arthritis diagnosed by a physician, N (%)	28 (28.9)	112 (25.4)	0.52
Prescription topical medication used in the last week, median (IQR), days	0 (0-0)	3 (0-7)	<0.001 ^b
Any prescription topical medication use in the last week, N (%)	22 (22.7)	289 (65.5)	<0.001
Current therapy ^d , N (%)			
Single therapy	66 (68.0)	341 (77.3)	0.07
Biologic	48 (72.7)	185 (54.2)	0.006
Oral Systemic	14 (21.2)	81 (23.8)	0.75
Light	4 (6.1)	75 (22.0)	0.002
Combination therapy	31 (32.0)	100 (22.7)	0.07
Biologic, oral systemic	24 (77.4)	46 (46.0)	0.003
Biologic, light	3 (9.7)	15 (15.0)	0.56
Oral systemic, light	2 (6.4)	22 (22.0)	0.06
Other	2 (6.4)	17 (17.0)	0.24
Number of current therapies ^e , N (%)			0.09
1	66 (68.1)	341 (77.3)	
2	30 (30.9)	92 (20.9)	
3	1 (1.0)	8 (1.8)	

^aFisher's exact test^bWilcoxon rank-sum test^cPercentages do not total 100% because 17.1% and 7.1% of patients with clear and almost clear skin, respectively, answered "do not know"^dPercentages of biologic, oral systemic, and light therapies are calculated among those on single therapy only. Percentages of biologic and oral systemic, biologic and light, oral systemic and light, and other combination therapies are calculated among those on combination therapies only^eCurrent therapy count includes any biologic, oral systemic, or light therapies only

Table 3

Dermatology Life Quality Index in Patients with Clear or Almost Clear Skin.

	Clear (PGA = 0) N = 97	Almost Clear (0 < PGA < 1.5) N = 441	P value ^a
DLQI, median (IQR)	0 (0, 1)	2 (0, 5)	<0.001 ^b
DLQI bands, N (%)			<0.001
0–1 No effect	74 (76.3)	194 (44.2)	
2–5 Small effect	21 (21.7)	160 (36.4)	
6–10 Moderate effect	1 (1.0)	56 (12.8)	
11–20 Very large effect	1 (1.0)	22 (5.0)	
21–30 Extremely large effect	0 (0)	7 (1.6)	
DLQI 0–5 No-small effect, N (%)	95 (97.9)	354 (80.6)	<0.001

Abbreviations: DLQI, Dermatology Life Quality Index; IQR, interquartile range; PGA, Physician Global Assessment

^aFisher's exact test^bWilcoxon rank-sum test

Table 4

Relative Risk of Dermatology Life Quality Index Outcome^a and Number Needed to Treat for Clear Versus Almost Clear Skin

Clinical Measure Defining Clear vs. Almost Clear Skin	Unadjusted RR (95% CI)	Adjusted RR ^b (95% CI)	NNT ^b (95% CI)
PGA ^c	1.73 (1.48–2.01)	1.60 (1.37–1.86)	3.8 (2.8–6.4)
Sensitivity Analyses			
Clear vs. almost clear defined by PGA = 0 vs. 0 < PGA – 1	1.60 (1.36–1.89)	1.49 (1.27–1.74)	4.3 (3.0–8.5)
Outcome redefined by DLQI – 5	1.21 (1.15–1.28)	1.19 (1.12–1.27)	6.4 (5.0–11.5)
Clear vs. almost clear defined by PASI ^d	1.64 (1.42–1.89)	1.53 (1.32–1.77) ^e	4.0 (2.9–6.9) ^e
Limited to BSA < 3	1.53 (1.31–1.79)	1.48 (1.26–1.73)	4.2 (3.0–7.9)
Exclude patients with mild psoriasis at worst	1.72 (1.46–2.02)	1.60 (1.36–1.89)	3.7 (2.8–6.4)
Exclude patients with PsA	1.72 (1.42–2.09)	1.57 (1.30–1.89)	4.2 (2.8–9.2)

Abbreviations: BSA, body surface area; CI, confidence interval; DLQI, Dermatology Life Quality Index; NNT, number needed to treat; PASI, Psoriasis Area and Severity Index; PGA, Physician Global Assessment; PsA, psoriatic arthritis; RR, relative risk.

^aDLQI – 1 unless otherwise noted

^bAdjusted for age, sex, practice site, marital status

^cPGA 0 vs. (0, 1.5)

^dPASI 0 vs. (0, 3)

^eAdjusted for age, sex, practice site, race, marital status, psoriasis severity at its worst